SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical & translational oncology 2024-11, Vol.26 (11), p.2856-2865
Hauptverfasser:	Vaz-Salgado, María Ángeles, García, Belén Cigarral, Pérez, Isaura Fernández, Munárriz, Beatriz Jiménez, Domarco, Paula Sampedro, González, Ainhoa Hernández, Villar, María Vieito, Caro, Raquel Luque, Delgado, María Luisa Villamayor, Sánchez, Juan Manuel Sepúlveda
Format:	Artikel
Sprache:	eng
Schlagworte:	Astrocytoma - genetics Astrocytoma - pathology Astrocytoma - therapy Brain Neoplasms - genetics Brain Neoplasms - pathology Brain Neoplasms - therapy Clinical Guides in Oncology Glioma - genetics Glioma - pathology Glioma - therapy Humans Isocitrate Dehydrogenase - genetics Medicine Medicine & Public Health Neoplasm Grading Oligodendroglioma - genetics Oligodendroglioma - pathology Oligodendroglioma - therapy Oncology Societies, Medical
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
ISSN:	1699-3055 1699-048X 1699-3055
DOI:	10.1007/s12094-024-03456-x